Our cerium oxide nanoparticles are conjugated to a micro-Ribonucleic Acid (miRNA) via a proprietary and patented platform technology. Currently, our first clinical candidate, CNP-miR146a is in pre-clinical development. Mir-146a acts a “molecular brake” for the inflammatory and oxidative stress pathways.

We have received favorable responses from the Food and Drug Administration (FDA) regarding two Pre-Investigational New Drug (IND) applications. CeriaTx is accelerating IND enabling pre-clinical studies in preparation of filing IND applications for both indications:

CNP-miR146a has activity in other disorders associated with inflammation and oxidative stress. Future indications with significant unmet need may include therapeutic areas such as colitis and expanding to acute respiratory distress syndrome (ARDS) without COVID-19 infection.